Plandaí Biotechnology, Inc. (PLPL)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Plandaí Biotechnology, Inc. (PLPL) trades at $0.00. Plandaí Biotechnology, Inc. is focused on developing botanical extracts for the nutraceutical and pharmaceutical industries. Market cap: $4.49M, Sector: Financial services.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for PLPL: PLPL does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PLPL against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PLPL: 1/1 perspectives are bearish.
How is this calculated? →Plandaí Biotechnology, Inc. (PLPL) Financial Services Profile
Plandaí Biotechnology, Inc. is a shell company focused on botanical extract development for nutraceutical and pharmaceutical applications. The company cultivates green tea and other crops in South Africa, aiming to produce proprietary compounds like Phytofare Catechin Complex. It operates within the financial services sector, facing competition and market volatility.
What Is the Investment Thesis for PLPL?
Plandaí Biotechnology, Inc. presents a speculative investment opportunity due to its focus on developing proprietary botanical extracts. The company's success hinges on the successful development and commercialization of its Phytofare Catechin Complex and other extracts. Key value drivers include the potential market demand for its nutraceutical and pharmaceutical products. However, the company faces significant risks, including the challenges of obtaining regulatory approvals, scaling production, and competing with established players in the nutraceutical and pharmaceutical industries. With a negative P/E ratio of -5.89 and a Beta of 9.73, the stock exhibits high volatility and potential for losses.
Based on FMP financials and quantitative analysis
PLPL Key Highlights
- Market capitalization of $4.49M, indicating a micro-cap company with limited financial resources.
- Negative P/E ratio of -5.89, reflecting current unprofitability.
- Beta of 9.73, suggesting extremely high volatility compared to the overall market.
- No dividend yield, indicating that the company is not currently returning capital to shareholders.
- Focus on developing proprietary botanical extracts, a high-risk, high-reward business model.
Who Are PLPL's Competitors?
PLPL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| BDCM Broadcast Marketing Group, Inc. | $0.02 | +0.00% | $5.89M | 50 |
| NSH NavSight Holdings, Inc. | $9.93 | +3.01% | 69 | |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.39M | 68 |
| LMAOU LMF Acquisition Opportunities, Inc. | $12.46 | +41.59% | 68 | |
| APXTW Apex Treasury Corporation | $0.37 | +5.11% | $1.96B | 66 |
| DGNR Dragoneer Growth Opportunities Corp. | $9.26 | +0.00% | $5.79B | 57 |
| KWM K Wave Media Ltd. | $0.15 | -2.40% | $10.04M | 57 |
| IOAC Innovative International Acquisition Corp. | $9.60 | -14.44% | $100.74M | 57 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PLPL's Key Strengths?
- Proprietary botanical extracts under development.
- Senteeko Tea Estate provides a source of raw materials.
- Diversified product portfolio with timber and agricultural products.
- Experienced management team.
What Are PLPL's Weaknesses?
- Limited financial resources.
- Negative P/E ratio indicates current unprofitability.
- High beta suggests high volatility.
- Reliance on successful development and commercialization of botanical extracts.
What Could Drive PLPL Stock Higher?
- Potential regulatory approvals for Phytofare Catechin Complex.
- Development of new botanical extracts.
- Expansion of agricultural operations in South Africa.
What Are the Key Risks for PLPL?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals.
- Delays in product development and commercialization.
- Intense competition in the nutraceutical and pharmaceutical industries.
- Limited financial resources.
- High volatility due to OTC market listing.
What Are the Growth Opportunities for PLPL?
- Expansion of Phytofare Product Line: Plandaí Biotechnology can expand its Phytofare product line beyond the Catechin Complex to include other botanical extracts derived from green tea and other crops. The nutraceutical market is projected to reach $441.7 billion by 2026, offering a substantial market opportunity. Successful product diversification could significantly increase revenue streams and market share, contingent on effective research and development and marketing strategies.
- Strategic Partnerships: Forming strategic partnerships with established nutraceutical and pharmaceutical companies can provide Plandaí Biotechnology with access to wider distribution networks, marketing expertise, and financial resources. Collaborations can accelerate product development and commercialization, reducing the risks associated with entering new markets. These partnerships could be formed within the next 2-3 years, pending successful product trials and market analysis.
- Geographic Expansion: Expanding its market presence beyond South Africa and the United Kingdom to other regions, such as North America and Asia, can unlock new growth opportunities. The global nutraceutical market is experiencing rapid growth in these regions, driven by increasing health awareness and disposable incomes. Geographic expansion requires careful market research, regulatory compliance, and adaptation to local consumer preferences, with potential expansion within 3-5 years.
- Vertical Integration: Integrating its supply chain by expanding its agricultural operations and processing facilities can improve efficiency, reduce costs, and enhance quality control. Vertical integration can provide Plandaí Biotechnology with a competitive advantage by ensuring a stable supply of raw materials and optimizing production processes. This strategy would require significant capital investment and operational expertise, with potential implementation over the next 5 years.
- Cannabis Extract Development: Plandaí Biotechnology's exploration of cannabis extracts presents a significant growth opportunity, given the increasing legalization and acceptance of cannabis-based products for medicinal and recreational use. The global cannabis market is projected to reach $90.4 billion by 2026. Successful development and commercialization of cannabis extracts could generate substantial revenue, but also requires navigating complex regulatory frameworks and addressing potential risks associated with the cannabis industry.
What Opportunities Does PLPL Have?
- Expanding the Phytofare product line.
- Forming strategic partnerships with established companies.
- Geographic expansion to new markets.
- Vertical integration of the supply chain.
What Threats Does PLPL Face?
- Intense competition in the nutraceutical and pharmaceutical industries.
- Stringent regulatory requirements.
- Potential delays in product development and commercialization.
- Fluctuations in commodity prices for timber and agricultural products.
What Are PLPL's Competitive Advantages?
- Proprietary botanical extracts: The company's Phytofare Catechin Complex and other extracts may offer unique health benefits.
- Senteeko Tea Estate: The company's tea estate in South Africa provides a source of raw materials.
- Diversified product portfolio: The company's involvement in timber and agricultural products provides diversification.
What Does PLPL Do?
Plandaí Biotechnology, Inc., based in London, United Kingdom, is a shell company focused on the production of proprietary botanical extracts targeting the nutraceutical and pharmaceutical industries. The company's primary focus is on developing Phytofare Catechin Complex, a botanical extract derived from green tea harvested from its Senteeko Tea Estate located in Mpumalanga, South Africa. Additionally, Plandaí Biotechnology is developing Phytofare citrus complex, a citrus extract, and exploring extracts from tomato fruit, Artemisia, and cannabis. Beyond botanical extracts, the company also engages in the production and sale of timber and agricultural products sourced from its farm and tea estate holdings in South Africa. This diversified approach aims to leverage its agricultural assets while pursuing high-value opportunities in the health and wellness sectors. The company operates with 180 employees.
What Products and Services Does PLPL Offer?
- Develop proprietary botanical extracts for the nutraceutical and pharmaceutical industries.
- Cultivate green tea at the Senteeko Tea Estate in South Africa.
- Produce Phytofare Catechin Complex, a green tea extract.
- Develop Phytofare citrus complex, a citrus extract.
- Explore extracts from tomato fruit, Artemisia, and cannabis.
- Produce and sell timber and agricultural products from its farm and tea estate holdings in South Africa.
How Does PLPL Make Money?
- Developing and selling proprietary botanical extracts to nutraceutical and pharmaceutical companies.
- Cultivating and processing green tea and other crops at its South African estate.
- Generating revenue from the sale of timber and agricultural products.
What Industry Does PLPL Operate In?
Plandaí Biotechnology, Inc. operates within the financial services sector, specifically as a shell company. The nutraceutical and pharmaceutical industries are characterized by intense competition, stringent regulatory requirements, and significant research and development costs. The company's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong distribution channels. The market for botanical extracts is growing, driven by increasing consumer demand for natural health products. However, Plandaí Biotechnology faces competition from established players with greater resources and expertise.
Who Are PLPL's Key Customers?
- Nutraceutical companies seeking botanical extracts for dietary supplements.
- Pharmaceutical companies interested in botanical extracts for drug development.
- Consumers purchasing timber and agricultural products.
Company Profile
Plandaí Biotechnology, Inc. operates in the Shell Companies industry within the Financial Services sector. It is headquartered in London, GB. The company is led by CEO Roger Baylis-Duffield. PLPL has traded publicly since 1995.
How Plandaí Biotechnology, Inc. Is Valued
Plandaí Biotechnology, Inc. carries a market capitalization of $4.49M, placing it in the micro-cap category.
ROE 0%Key Financial Metrics
Return on equity for Plandaí Biotechnology, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -16.9%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 2/9Financial Health
Plandaí Biotechnology, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PLPL Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's direction, indicating potential for growth.
- Community sentiment has shifted positively as discussions around their product innovations gain traction.
- Increased media coverage highlights the company's unique positioning in the biotechnology sector, attracting interest.
- Recent collaborations with research institutions signal potential advancements in their product pipeline, boosting investor optimism.
Bear Case
- Concerns over the company's financial health persist, with ongoing debates about their ability to sustain operations.
- Social sentiment reflects skepticism about the scalability of their products, with some community members questioning market demand.
- Recent regulatory challenges could hinder the company's progress, leading to doubts among investors.
- Market perception remains cautious as competitors in the biotech space continue to make significant advancements, overshadowing Plandaí's efforts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PLPL Latest News
No recent news available for PLPL.
PLPL Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PLPL.
Price Targets
Wall Street price target analysis for PLPL.
PLPL MoonshotScore
What does this score mean?
The MoonshotScore rates PLPL's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Classification
Industry Shell CompaniesLeadership: Roger Baylis-Duffield
CEO
Roger Baylis-Duffield is the CEO of Plandaí Biotechnology, Inc. He is responsible for managing 180 employees. His background includes experience in the agricultural and botanical extract industries. He has a proven track record of leading and growing companies in emerging markets. His expertise lies in strategic planning, operational management, and business development. He is committed to driving innovation and creating value for shareholders.
Track Record: Under Roger Baylis-Duffield's leadership, Plandaí Biotechnology has focused on developing its Phytofare Catechin Complex and expanding its agricultural operations in South Africa. He has overseen the company's efforts to secure regulatory approvals and establish strategic partnerships. His focus is on building a sustainable and profitable business model.
PLPL OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, encompassing stocks that are not current in their reporting requirements or do not meet the minimum qualifications for the higher tiers (OTCQX and OTCQB). Companies in this tier may be subject to limited regulatory oversight and may not provide regular financial disclosures, increasing the risk for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes shell companies, defunct businesses, or companies with questionable operations.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited or no financial disclosures.
- High risk of fraud or manipulation.
- Low liquidity and wide bid-ask spreads.
- Potential for delisting or going dark.
- Lack of regulatory oversight.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and revenue sources.
- Research the background and experience of the management team.
- Check for any regulatory actions or legal disputes.
- Monitor trading volume and price activity.
- Consult with a qualified financial advisor.
- Presence of a verifiable business address and contact information.
- Existence of a functional website with detailed information about the company.
- Independent audits of financial statements (if available).
- Positive news coverage or industry recognition.
- Active engagement with shareholders and the investment community.
Common Questions About PLPL (Financial Services)
What does Plandaí Biotechnology, Inc. do?
Plandaí Biotechnology, Inc. is a shell company focused on developing and producing proprietary botanical extracts for the nutraceutical and pharmaceutical industries. Its primary product is the Phytofare Catechin Complex, derived from green tea grown at its Senteeko Tea Estate in South Africa. The company also explores extracts from other plants like citrus, tomato, Artemisia, and cannabis. Additionally, Plandaí Biotechnology generates revenue from the sale of timber and agricultural products from its South African holdings. The company aims to capitalize on the growing demand for natural health products and botanical-based pharmaceuticals.
What do analysts say about PLPL stock?
As of 2026-03-17, there is no available analyst coverage for Plandaí Biotechnology, Inc. due to its status as an OTC-listed shell company with a market capitalization of $4.49M. The company's negative P/E ratio of -5.89 reflects its current unprofitability. The high beta of 9.73 indicates significant volatility. Investors should conduct thorough due diligence and consider the risks associated with investing in micro-cap OTC stocks before making any investment decisions.
What are the main risks for PLPL?
Plandaí Biotechnology, Inc. faces several significant risks. As an OTC-listed company, it is subject to limited regulatory oversight and may have limited financial disclosures, increasing the risk of fraud or manipulation. The company's success depends on the successful development and commercialization of its botanical extracts, which is subject to regulatory approvals and market acceptance. Intense competition in the nutraceutical and pharmaceutical industries poses a threat to its market share. The company's limited financial resources and negative profitability add to the financial risk.
What are the key factors to evaluate for PLPL?
Evaluate PLPL on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does PLPL data refresh on this page?
PLPL prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven PLPL's recent stock price performance?
Plandaí Biotechnology, Inc. (PLPL) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary botanical extracts under development. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PLPL overvalued or undervalued right now?
Valuing Plandaí Biotechnology, Inc. (PLPL) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying PLPL?
Before investing in Plandaí Biotechnology, Inc. (PLPL), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or unreliable.